Risultati di ricerca
13 dic 2019 · Lo scopo principale di queste linee guida pratiche relative alla malattia di Kawasaki (KD) è quello di contribuire alla diagnosi tempestiva e al trattamento appropriato sulla base dei contributi di diversi specialisti nel settore.
- Per i medici
Istituito il premio Mauro Bozzola. La Società Italiana di...
- Per i medici
- Abstract
- Scope
- Users
- Sponsorships
- Updates
- Treatment of resistant forms of Kawasaki disease
- Corticosteroids
- Anti-angina drugs and coronary artery vasodilators
- Statins
- Indications
- Fitness certification for patients with a previous Kawasaki disease
- Conclusion
- Abbreviations
- Acknowledgements
- Funding
- Availability of data and materials
- Competing interests
- Publisher’s Note
This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 rec...
Scope of these revised Guidelines is to update evidence on the following topics:
These Guidelines are directed to pediatricians who work in hospital, family pediatricians, and general practi-tioners who work with children affected by KD and for families of KD patients.
No person who participated in the drafting of these Guidelines has been sponsored.
Future updates are planned within the next five years, or sooner, if the medical literature will reveal evidences showing that these Guidelines have become obsolete.
Several second-line treatment options are available in the resistant KD, represented by additional IVIG infusions, intravenous methylprednisolone pulses, infliximab, ulinastatin, cyclosporine A, methotrexate, and plasmapheresis. Clinical trials for anakinra or canakinumab are ongoing. Randomized controlled trials that evaluated the effectiveness of...
Corticosteroids are usually administered in all vasculitides due to their immunosuppressive and anti-inflammatory effect, with the aim of blocking the potential risk of CAA in KD. Their use as first and second-line treatment is de-bated, because of the differences regarding the selection of patients (all patients versus high-risk patients) and the ...
In KD patients younger than 2 years, symptoms of an-gina are rare. The main purpose of the anti-angina ther-apy is reducing heart rate and cardiac workload, reducing pre- and afterload, and increasing the coronary artery flow. Drugs of this group are beta-blockers, cal-cium channel blockers and nitro-vasodilators (see Table 6). Beta-blockers are th...
Hydroxymethylglutaryl coenzyme-A reductase inhibitors (statins) are a cornerstone of therapy for the primary and secondary prevention of atherosclerotic cardiovascu-lar events in adults. They reduce low-density lipoprotein cholesterol and have potentially beneficial pleiotropic ef-fects on inflammation, endothelial function, oxidative stress, plate...
Patients with a significant left ventricular dysfunction. Patients with potentially lethal arrhythmias. Patients with significant lesions in the peripheral segments of the coronary arteries.
Reference personnel for patients with a previous KD who want to perform agonistic sports (competitive sports or high-intensity activities) includes doctors specialized in sports medicine who work in the health systems or in authorized private structures; certification for non-agonistic sports can be provided by the family pediatrician and practitio...
This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to the most appropriate treatment of resistant forms and KD-related cardiovascular/systemic complications, follow-up, lifestyle and prevention of long-term risks through a set of 17 recommendations. These are based on the most actual scientific ev...
ASA: Acetylsalicylic acid; AST: Aspartate aminotransferase; ATIII: Antitrombin III; CAA: Coronary artery aneurysms; CABG: Coronary artery bypass grafting; CRP: C-reactive protein; CT: Computed tomography; ECG: Electrocardiogram; IFX: Infliximab; IL: Interleukin; INR: International normalized ratio; IVIG: Intravenous immunoglobulin; KD: Kawasaki dis...
We would like to thank prof. Alessio Maria (Università degli Studi di Napoli Federico II, Naples), dr. Granato Carmen (Università degli Studi di Napoli Federico II, Naples) and dr. Marotta Rosaria (Università degli Studi di Napoli Federico II, Naples).
No person who participated in the drafting of these guidelines has been sponsored.
No datasets were generated or analyzed during the current study.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1MB
- 18
MALATTIA DI KAWASAKI: LINEE GUIDA DELLA SOCIETA’ ITALIANA DI PEDIATRIA. A cura di: Marchesi A, Ferro G, Tarissi de Jacobis I, Villani A. U.O.C. Pediatria Generale e Malattie Infettive.
23 apr 2022 · La nuova linea guida sulla gestione della sindrome di Kawasaki si è focalizzata sulle problematiche di gestione cliniche generalmente poste ai reumatologi, come l’impiego di...
Scopo di queste Linee Guida (LG) è definire: le evidenze sulla possibile eziopatogenesi della malattia di Kawasaki; le evidenze sull’accuratezza di segni e sintomi clinici, diagnosti-ca di laboratorio e per immagini; le evidenze di efficacia della terapia della fase acuta con immu-noglobuline endovena ed aspirina;
La malattia di Kawasaki è una vasculite infantile sistemica a eziologia sconosciuta; è la principale causa di cardiopatia acquisita nei bambini. Le complicanze più gravi riguardano il cuore e comprendono la miocardite acuta con insufficienza cardiaca, aritmie e aneurismi delle arterie coronarie.
30 ago 2018 · The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists' contributions in the field.
